Juvenile Macular Degeneration (Stargardt Disease) Treatment Market - Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: J0D97990ED03EN
Market Monitor Global

Abstracts

Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.

This report contains market size and forecasts of Juvenile Macular Degeneration (Stargardt Disease) Treatment in Global, including the following market information:

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Juvenile Macular Degeneration (Stargardt Disease) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Stem Cell Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Juvenile Macular Degeneration (Stargardt Disease) Treatment include Sanofi, Bayer, Roche, Pfizer, Allergan, Gilead Sciences, Kubota Pharmaceutical, Alkeus Pharmaceuticals and Astellas Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Juvenile Macular Degeneration (Stargardt Disease) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Segment Percentages, by Type, 2021 (%)

• Stem Cell Therapy
• Gene Therapy
• Others

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Eye Clinics
• Others

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Juvenile Macular Degeneration (Stargardt Disease) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Juvenile Macular Degeneration (Stargardt Disease) Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi
• Bayer
• Roche
• Pfizer
• Allergan
• Gilead Sciences
• Kubota Pharmaceutical
• Alkeus Pharmaceuticals
• Astellas Pharma
• Ferrer Corporate

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL JUVENILE MACULAR DEGENERATION (STARGARDT DISEASE) TREATMENT OVERALL MARKET SIZE

2.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size: 2021 VS 2028
2.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players in Global Market
3.2 Top Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies Ranked by Revenue
3.3 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Markets, 2021 & 2028
  4.1.2 Stem Cell Therapy
  4.1.3 Gene Therapy
  4.1.4 Others
4.2 By Type - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue & Forecasts
  4.2.1 By Type - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Eye Clinics
  5.1.4 Others
5.2 By Application - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue & Forecasts
  5.2.1 By Application - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2021 & 2028
6.2 By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue & Forecasts
  6.2.1 By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2028
  6.3.2 US Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.3.3 Canada Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.3.4 Mexico Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2028
  6.4.2 Germany Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.4.3 France Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.4.4 U.K. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.4.5 Italy Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.4.6 Russia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.4.8 Benelux Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2028
  6.5.2 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.5.3 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.5.4 South Korea Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.5.6 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2028
  6.6.2 Brazil Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.6.3 Argentina Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2028
  6.7.2 Turkey Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.7.3 Israel Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028
  6.7.5 UAE Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Sanofi
  7.1.1 Sanofi Corporate Summary
  7.1.2 Sanofi Business Overview
  7.1.3 Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.1.4 Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.1.5 Sanofi Key News
7.2 Bayer
  7.2.1 Bayer Corporate Summary
  7.2.2 Bayer Business Overview
  7.2.3 Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.2.4 Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.2.5 Bayer Key News
7.3 Roche
  7.3.1 Roche Corporate Summary
  7.3.2 Roche Business Overview
  7.3.3 Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.3.4 Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.3.5 Roche Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.4.4 Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.4.5 Pfizer Key News
7.5 Allergan
  7.5.1 Allergan Corporate Summary
  7.5.2 Allergan Business Overview
  7.5.3 Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.5.4 Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.5.5 Allergan Key News
7.6 Gilead Sciences
  7.6.1 Gilead Sciences Corporate Summary
  7.6.2 Gilead Sciences Business Overview
  7.6.3 Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.6.4 Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.6.5 Gilead Sciences Key News
7.7 Kubota Pharmaceutical
  7.7.1 Kubota Pharmaceutical Corporate Summary
  7.7.2 Kubota Pharmaceutical Business Overview
  7.7.3 Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.7.4 Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.7.5 Kubota Pharmaceutical Key News
7.8 Alkeus Pharmaceuticals
  7.8.1 Alkeus Pharmaceuticals Corporate Summary
  7.8.2 Alkeus Pharmaceuticals Business Overview
  7.8.3 Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.8.4 Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.8.5 Alkeus Pharmaceuticals Key News
7.9 Astellas Pharma
  7.9.1 Astellas Pharma Corporate Summary
  7.9.2 Astellas Pharma Business Overview
  7.9.3 Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.9.4 Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.9.5 Astellas Pharma Key News
7.10 Ferrer Corporate
  7.10.1 Ferrer Corporate Corporate Summary
  7.10.2 Ferrer Corporate Business Overview
  7.10.3 Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Major Product Offerings
  7.10.4 Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global Market (2017-2022)
  7.10.5 Ferrer Corporate Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Opportunities & Trends in Global Market
Table 2. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Drivers in Global Market
Table 3. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Restraints in Global Market
Table 4. Key Players of Juvenile Macular Degeneration (Stargardt Disease) Treatment in Global Market
Table 5. Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Type
Table 9. List of Global Tier 1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 32. Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Bayer Corporate Summary
Table 34. Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 35. Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Roche Corporate Summary
Table 37. Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 38. Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 41. Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Allergan Corporate Summary
Table 43. Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 44. Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Gilead Sciences Corporate Summary
Table 46. Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 47. Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Kubota Pharmaceutical Corporate Summary
Table 49. Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 50. Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Alkeus Pharmaceuticals Corporate Summary
Table 52. Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 53. Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Astellas Pharma Corporate Summary
Table 55. Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 56. Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Ferrer Corporate Corporate Summary
Table 58. Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Offerings
Table 59. Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Juvenile Macular Degeneration (Stargardt Disease) Treatment Segment by Type in 2021
Figure 2. Juvenile Macular Degeneration (Stargardt Disease) Treatment Segment by Application in 2021
Figure 3. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in 2021
Figure 8. By Type - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 12. US Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 24. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)